Rare Chance Or Passing Opportunity: China Expands Orphan Drug Coverage With Steep Price Cuts

Latest national medical insurance negotiations results show orphan drugs are covered, but Biogen’s Spinraza gets a 95% price cut. Getting coverage, rather holding out for a high price, really makes more sense in the emerging Chinese market for rare disease drugs, industry observers say.